Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles E Geyer

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
The Lancet. Oncology|February 14, 2018
Clinical trials in older, less fit populations: an unmet need?Charles E Geyer
Lancet (London, England)|March 7, 2006
Trastuzumab for early breast cancerJohn Bryant, Charles E Geyer
Women'S Health (London, England)|February 28, 2009
Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancerBushra Haq, Charles E Geyer
Breast (Edinburgh, Scotland)|March 27, 2025
Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapyCharles E Geyer, Sibylle Loibl
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2019
Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?Masey Ross, Charles E Geyer
Seminars in Oncology Nursing|January 26, 2008
Overcoming treatment challenges in advanced breast cancerBarbara Harkins, Charles E Geyer
Annals of Surgical Oncology|March 3, 2015
Pathological complete response in neoadjuvant treatment of breast cancerPatricia Cortazar, Charles E Geyer
Cell Research|May 8, 2023
Precision medicine for metastatic TNBC: the FUTURE is nowJulia Foldi, Charles E Geyer
Journal of the National Cancer Institute|December 27, 2007
Anthracyclines in the treatment of HER2-negative breast cancerSoonmyung Paik, Yusuke Taniyama, Charles E Geyer
Current Oncology Reports|March 28, 2008
The emerging role of lapatinib in HER2-positive breast cancerAlice Ulhoa-Cintra, Larisa Greenberg, Charles E Geyer
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|February 14, 2018
Clinical trials in older, less fit populations: an unmet need?Charles E Geyer
Lancet (London, England)|March 7, 2006
Trastuzumab for early breast cancerJohn Bryant, Charles E Geyer
Women'S Health (London, England)|February 28, 2009
Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancerBushra Haq, Charles E Geyer
Breast (Edinburgh, Scotland)|March 27, 2025
Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapyCharles E Geyer, Sibylle Loibl
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2019
Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer?Masey Ross, Charles E Geyer
Seminars in Oncology Nursing|January 26, 2008
Overcoming treatment challenges in advanced breast cancerBarbara Harkins, Charles E Geyer
Annals of Surgical Oncology|March 3, 2015
Pathological complete response in neoadjuvant treatment of breast cancerPatricia Cortazar, Charles E Geyer
Cell Research|May 8, 2023
Precision medicine for metastatic TNBC: the FUTURE is nowJulia Foldi, Charles E Geyer
Journal of the National Cancer Institute|December 27, 2007
Anthracyclines in the treatment of HER2-negative breast cancerSoonmyung Paik, Yusuke Taniyama, Charles E Geyer
Current Oncology Reports|March 28, 2008
The emerging role of lapatinib in HER2-positive breast cancerAlice Ulhoa-Cintra, Larisa Greenberg, Charles E Geyer
Pageof 13